Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Resmetirom

MARKETED

Thyroid hormone receptor beta agonist

1
graded results
0
ongoing records
1
effect domains
Evidence spread
High evidence 0Moderate evidence 1Low evidence 0Very low evidence 0

Resmetirom has a current marketed status in the scoped regulatory record below. Results describe observations and do not provide treatment advice.

Dated status sources

MARKETED United States; Noncirrhotic MASH with moderate-to-advanced fibrosis; Oral tablet; as of 2026-07-13. US Food and Drug Administration

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Resmetirom MARKETED
Liver and MASH Decrease
Moderate evidence

CONTEXT BENCHMARK (NON-incretin). Resmetirom (Rezdiffra, Madrigal) is the FIRST FDA-approved MASH drug, approved on the MAESTRO-NASH histological co-primaries....

Harrison SA, Bedossa P et al. MAESTRO-NASH. N Engl J Med 2024;390:497-509. Source
Full findingCONTEXT BENCHMARK (NON-incretin). Resmetirom (Rezdiffra, Madrigal) is the FIRST FDA-approved MASH drug, approved on the MAESTRO-NASH histological co-primaries. Included as the regulatory/efficacy benchmark against which incretin MASH efficacy is read, NOT as a class finding. Like ESSENCE it gained accelerated approval on histological SURROGATES; hard-outcome confirmation has not yet read out. Cross-trial comparison with ESSENCE is informal only (different populations, no head-to-head).
PopulationMAESTRO-NASH (NCT03900429), phase 3, 3 arms (80/100 mg/placebo), n=966 primary-analysis. Biopsy NASH fibrosis F1B/F2/F3; F4/CIRRHOSIS EXCLUDED. 52 wk.
Fundingindustry - Madrigal Pharmaceuticals
Comparatorsplacebo; resmetirom 80 mg; resmetirom 100 mg